

COVID-19 Impact on Global Targeted Drugs for NSCLC Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C693BF5793B3EN.html>

Date: July 2020

Pages: 153

Price: US\$ 3,900.00 (Single User License)

ID: C693BF5793B3EN

Abstracts

This report focuses on the global Targeted Drugs for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drugs for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Allergan

Amgen

ARIAD Pharmaceuticals (Takeda)

Beacon Pharma Limited

BeiGene

Biocon

Boehringer-Ingelheim

Celgene Corporation

Drug International Limited

Fujifilm Kyowa Kirin Biologics

Genvio Pharma Limited

Hetero Drugs

ImClone Systems ?(Eli Lilly)

Incepta Pharmaceuticals

Mylan

Novartis

Pfizer

Reliance Lifesciences

Roche

AstraZeneca

Cipla

Teva

OSI Pharmaceuticals

Glenmark Pharmaceuticals

Natco Pharma

Market segment by Type, the product can be split into

Target EGFR

Target ALK

Target HER2

Target ROS1

Target BRAF

Target MEK

Target VEGFR2

Target VEGF

Target MET

Market segment by Application, split into

Squamous Cell Carcinoma of NSCLC

Adenocarcinoma of NSCLC

Large Cell Carcinoma of NSCLC

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Targeted Drugs for NSCLC status, future forecast, growth opportunity, key market and key players.

To present the Targeted Drugs for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Targeted Drugs for NSCLC are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Targeted Drugs for NSCLC Revenue

1.4 Market Analysis by Type

1.4.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Target EGFR

1.4.3 Target ALK

1.4.4 Target HER2

1.4.5 Target ROS1

1.4.6 Target BRAF

1.4.7 Target MEK

1.4.8 Target VEGFR2

1.4.9 Target VEGF

1.4.10 Target MET

1.5 Market by Application

1.5.1 Global Targeted Drugs for NSCLC Market Share by Application: 2020 VS 2026

1.5.2 Squamous Cell Carcinoma of NSCLC

1.5.3 Adenocarcinoma of NSCLC

1.5.4 Large Cell Carcinoma of NSCLC

1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drugs for NSCLC Industry Impact

1.6.1 How the Covid-19 is Affecting the Targeted Drugs for NSCLC Industry

1.6.1.1 Targeted Drugs for NSCLC Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Targeted Drugs for NSCLC Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Targeted Drugs for NSCLC Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

- 2.1 Targeted Drugs for NSCLC Market Perspective (2015-2026)
- 2.2 Targeted Drugs for NSCLC Growth Trends by Regions
 - 2.2.1 Targeted Drugs for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026
 - 2.2.2 Targeted Drugs for NSCLC Historic Market Share by Regions (2015-2020)
 - 2.2.3 Targeted Drugs for NSCLC Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
 - 2.3.1 Market Top Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Challenges
 - 2.3.4 Porter's Five Forces Analysis
 - 2.3.5 Targeted Drugs for NSCLC Market Growth Strategy
 - 2.3.6 Primary Interviews with Key Targeted Drugs for NSCLC Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Top Targeted Drugs for NSCLC Players by Market Size
 - 3.1.1 Global Top Targeted Drugs for NSCLC Players by Revenue (2015-2020)
 - 3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by Players (2015-2020)
 - 3.1.3 Global Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Targeted Drugs for NSCLC Market Concentration Ratio
 - 3.2.1 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
 - 3.2.2 Global Top 10 and Top 5 Companies by Targeted Drugs for NSCLC Revenue in 2019
- 3.3 Targeted Drugs for NSCLC Key Players Head office and Area Served
- 3.4 Key Players Targeted Drugs for NSCLC Product Solution and Service
- 3.5 Date of Enter into Targeted Drugs for NSCLC Market
- 3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

- 4.1 Global Targeted Drugs for NSCLC Historic Market Size by Type (2015-2020)
- 4.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2021-2026)

5 TARGETED DRUGS FOR NSCLC BREAKDOWN DATA BY APPLICATION (2015-2026)

- 5.1 Global Targeted Drugs for NSCLC Market Size by Application (2015-2020)
- 5.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

- 6.1 North America Targeted Drugs for NSCLC Market Size (2015-2020)
- 6.2 Targeted Drugs for NSCLC Key Players in North America (2019-2020)
- 6.3 North America Targeted Drugs for NSCLC Market Size by Type (2015-2020)
- 6.4 North America Targeted Drugs for NSCLC Market Size by Application (2015-2020)

7 EUROPE

- 7.1 Europe Targeted Drugs for NSCLC Market Size (2015-2020)
- 7.2 Targeted Drugs for NSCLC Key Players in Europe (2019-2020)
- 7.3 Europe Targeted Drugs for NSCLC Market Size by Type (2015-2020)
- 7.4 Europe Targeted Drugs for NSCLC Market Size by Application (2015-2020)

8 CHINA

- 8.1 China Targeted Drugs for NSCLC Market Size (2015-2020)
- 8.2 Targeted Drugs for NSCLC Key Players in China (2019-2020)
- 8.3 China Targeted Drugs for NSCLC Market Size by Type (2015-2020)
- 8.4 China Targeted Drugs for NSCLC Market Size by Application (2015-2020)

9 JAPAN

- 9.1 Japan Targeted Drugs for NSCLC Market Size (2015-2020)
- 9.2 Targeted Drugs for NSCLC Key Players in Japan (2019-2020)
- 9.3 Japan Targeted Drugs for NSCLC Market Size by Type (2015-2020)
- 9.4 Japan Targeted Drugs for NSCLC Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

- 10.1 Southeast Asia Targeted Drugs for NSCLC Market Size (2015-2020)
- 10.2 Targeted Drugs for NSCLC Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Targeted Drugs for NSCLC Market Size by Type (2015-2020)
- 10.4 Southeast Asia Targeted Drugs for NSCLC Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Targeted Drugs for NSCLC Market Size (2015-2020)
- 11.2 Targeted Drugs for NSCLC Key Players in India (2019-2020)
- 11.3 India Targeted Drugs for NSCLC Market Size by Type (2015-2020)
- 11.4 India Targeted Drugs for NSCLC Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

- 12.1 Central & South America Targeted Drugs for NSCLC Market Size (2015-2020)
- 12.2 Targeted Drugs for NSCLC Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Targeted Drugs for NSCLC Market Size by Type (2015-2020)
- 12.4 Central & South America Targeted Drugs for NSCLC Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

- 13.1 Allergan
 - 13.1.1 Allergan Company Details
 - 13.1.2 Allergan Business Overview and Its Total Revenue
 - 13.1.3 Allergan Targeted Drugs for NSCLC Introduction
 - 13.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2015-2020))
 - 13.1.5 Allergan Recent Development
- 13.2 Amgen
 - 13.2.1 Amgen Company Details
 - 13.2.2 Amgen Business Overview and Its Total Revenue
 - 13.2.3 Amgen Targeted Drugs for NSCLC Introduction
 - 13.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 13.2.5 Amgen Recent Development
- 13.3 ARIAD Pharmaceuticals (Takeda)
 - 13.3.1 ARIAD Pharmaceuticals (Takeda) Company Details
 - 13.3.2 ARIAD Pharmaceuticals (Takeda) Business Overview and Its Total Revenue
 - 13.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Introduction
 - 13.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 13.3.5 ARIAD Pharmaceuticals (Takeda) Recent Development
- 13.4 Beacon Pharma Limited

- 13.4.1 Beacon Pharma Limited Company Details
- 13.4.2 Beacon Pharma Limited Business Overview and Its Total Revenue
- 13.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Introduction
- 13.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020)
- 13.4.5 Beacon Pharma Limited Recent Development
- 13.5 BeiGene
 - 13.5.1 BeiGene Company Details
 - 13.5.2 BeiGene Business Overview and Its Total Revenue
 - 13.5.3 BeiGene Targeted Drugs for NSCLC Introduction
 - 13.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 13.5.5 BeiGene Recent Development
- 13.6 Biocon
 - 13.6.1 Biocon Company Details
 - 13.6.2 Biocon Business Overview and Its Total Revenue
 - 13.6.3 Biocon Targeted Drugs for NSCLC Introduction
 - 13.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 13.6.5 Biocon Recent Development
- 13.7 Boehringer-Ingelheim
 - 13.7.1 Boehringer-Ingelheim Company Details
 - 13.7.2 Boehringer-Ingelheim Business Overview and Its Total Revenue
 - 13.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Introduction
 - 13.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 13.7.5 Boehringer-Ingelheim Recent Development
- 13.8 Celgene Corporation
 - 13.8.1 Celgene Corporation Company Details
 - 13.8.2 Celgene Corporation Business Overview and Its Total Revenue
 - 13.8.3 Celgene Corporation Targeted Drugs for NSCLC Introduction
 - 13.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 13.8.5 Celgene Corporation Recent Development
- 13.9 Drug International Limited
 - 13.9.1 Drug International Limited Company Details
 - 13.9.2 Drug International Limited Business Overview and Its Total Revenue
 - 13.9.3 Drug International Limited Targeted Drugs for NSCLC Introduction
 - 13.9.4 Drug International Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 13.9.5 Drug International Limited Recent Development

13.10 Fujifilm Kyowa Kirin Biologics

13.10.1 Fujifilm Kyowa Kirin Biologics Company Details

13.10.2 Fujifilm Kyowa Kirin Biologics Business Overview and Its Total Revenue

13.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Introduction

13.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC

Business (2015-2020)

13.10.5 Fujifilm Kyowa Kirin Biologics Recent Development

13.11 Genvio Pharma Limited

10.11.1 Genvio Pharma Limited Company Details

10.11.2 Genvio Pharma Limited Business Overview and Its Total Revenue

10.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Introduction

10.11.4 Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business

(2015-2020)

10.11.5 Genvio Pharma Limited Recent Development

13.12 Hetero Drugs

10.12.1 Hetero Drugs Company Details

10.12.2 Hetero Drugs Business Overview and Its Total Revenue

10.12.3 Hetero Drugs Targeted Drugs for NSCLC Introduction

10.12.4 Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2015-2020)

10.12.5 Hetero Drugs Recent Development

13.13 ImClone Systems (Eli Lilly)

10.13.1 ImClone Systems (Eli Lilly) Company Details

10.13.2 ImClone Systems (Eli Lilly) Business Overview and Its Total Revenue

10.13.3 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Introduction

10.13.4 ImClone Systems (Eli Lilly) Revenue in Targeted Drugs for NSCLC Business

(2015-2020)

10.13.5 ImClone Systems (Eli Lilly) Recent Development

13.14 Incepta Pharmaceuticals

10.14.1 Incepta Pharmaceuticals Company Details

10.14.2 Incepta Pharmaceuticals Business Overview and Its Total Revenue

10.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Introduction

10.14.4 Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business

(2015-2020)

10.14.5 Incepta Pharmaceuticals Recent Development

13.15 Mylan

10.15.1 Mylan Company Details

10.15.2 Mylan Business Overview and Its Total Revenue

10.15.3 Mylan Targeted Drugs for NSCLC Introduction

10.15.4 Mylan Revenue in Targeted Drugs for NSCLC Business (2015-2020)

- 10.15.5 Mylan Recent Development
- 13.16 Novartis
 - 10.16.1 Novartis Company Details
 - 10.16.2 Novartis Business Overview and Its Total Revenue
 - 10.16.3 Novartis Targeted Drugs for NSCLC Introduction
 - 10.16.4 Novartis Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 10.16.5 Novartis Recent Development
- 13.17 Pfizer
 - 10.17.1 Pfizer Company Details
 - 10.17.2 Pfizer Business Overview and Its Total Revenue
 - 10.17.3 Pfizer Targeted Drugs for NSCLC Introduction
 - 10.17.4 Pfizer Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 10.17.5 Pfizer Recent Development
- 13.18 Reliance Lifesciences
 - 10.18.1 Reliance Lifesciences Company Details
 - 10.18.2 Reliance Lifesciences Business Overview and Its Total Revenue
 - 10.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Introduction
 - 10.18.4 Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 10.18.5 Reliance Lifesciences Recent Development
- 13.19 Roche
 - 10.19.1 Roche Company Details
 - 10.19.2 Roche Business Overview and Its Total Revenue
 - 10.19.3 Roche Targeted Drugs for NSCLC Introduction
 - 10.19.4 Roche Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 10.19.5 Roche Recent Development
- 13.20 AstraZeneca
 - 10.20.1 AstraZeneca Company Details
 - 10.20.2 AstraZeneca Business Overview and Its Total Revenue
 - 10.20.3 AstraZeneca Targeted Drugs for NSCLC Introduction
 - 10.20.4 AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 10.20.5 AstraZeneca Recent Development
- 13.21 Cipla
 - 10.21.1 Cipla Company Details
 - 10.21.2 Cipla Business Overview and Its Total Revenue
 - 10.21.3 Cipla Targeted Drugs for NSCLC Introduction
 - 10.21.4 Cipla Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 10.21.5 Cipla Recent Development
- 13.22 Teva

- 10.22.1 Teva Company Details
- 10.22.2 Teva Business Overview and Its Total Revenue
- 10.22.3 Teva Targeted Drugs for NSCLC Introduction
- 10.22.4 Teva Revenue in Targeted Drugs for NSCLC Business (2015-2020)
- 10.22.5 Teva Recent Development
- 13.23 OSI Pharmaceuticals
 - 10.23.1 OSI Pharmaceuticals Company Details
 - 10.23.2 OSI Pharmaceuticals Business Overview and Its Total Revenue
 - 10.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Introduction
 - 10.23.4 OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 10.23.5 OSI Pharmaceuticals Recent Development
- 13.24 Glenmark Pharmaceuticals
 - 10.24.1 Glenmark Pharmaceuticals Company Details
 - 10.24.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
 - 10.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Introduction
 - 10.24.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 10.24.5 Glenmark Pharmaceuticals Recent Development
- 13.25 Natco Pharma
 - 10.25.1 Natco Pharma Company Details
 - 10.25.2 Natco Pharma Business Overview and Its Total Revenue
 - 10.25.3 Natco Pharma Targeted Drugs for NSCLC Introduction
 - 10.25.4 Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2015-2020)
 - 10.25.5 Natco Pharma Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

- 15.1 Research Methodology
 - 15.1.1 Methodology/Research Approach
 - 15.1.2 Data Source
- 15.2 Disclaimer
- 15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Targeted Drugs for NSCLC Key Market Segments

Table 2. Key Players Covered: Ranking by Targeted Drugs for NSCLC Revenue

Table 3. Ranking of Global Top Targeted Drugs for NSCLC Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Targeted Drugs for NSCLC Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Target EGFR

Table 6. Key Players of Target ALK

Table 7. Key Players of Target HER2

Table 8. Key Players of Target ROS1

Table 9. Key Players of Target BRAF

Table 10. Key Players of Target MEK

Table 11. Key Players of Target VEGFR2

Table 12. Key Players of Target VEGF

Table 13. Key Players of Target MET

Table 14. COVID-19 Impact Global Market: (Four Targeted Drugs for NSCLC Market Size Forecast Scenarios)

Table 15. Opportunities and Trends for Targeted Drugs for NSCLC Players in the COVID-19 Landscape

Table 16. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 17. Key Regions/Countries Measures against Covid-19 Impact

Table 18. Proposal for Targeted Drugs for NSCLC Players to Combat Covid-19 Impact

Table 19. Global Targeted Drugs for NSCLC Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 20. Global Targeted Drugs for NSCLC Market Size by Regions (US\$ Million): 2020 VS 2026

Table 21. Global Targeted Drugs for NSCLC Market Size by Regions (2015-2020) (US\$ Million)

Table 22. Global Targeted Drugs for NSCLC Market Share by Regions (2015-2020)

Table 23. Global Targeted Drugs for NSCLC Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 24. Global Targeted Drugs for NSCLC Market Share by Regions (2021-2026)

Table 25. Market Top Trends

Table 26. Key Drivers: Impact Analysis

Table 27. Key Challenges

Table 28. Targeted Drugs for NSCLC Market Growth Strategy

Table 29. Main Points Interviewed from Key Targeted Drugs for NSCLC Players

Table 30. Global Targeted Drugs for NSCLC Revenue by Players (2015-2020) (Million US\$)

Table 31. Global Targeted Drugs for NSCLC Market Share by Players (2015-2020)

Table 32. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for NSCLC as of 2019)

Table 33. Global Targeted Drugs for NSCLC by Players Market Concentration Ratio (CR5 and HHI)

Table 34. Key Players Headquarters and Area Served

Table 35. Key Players Targeted Drugs for NSCLC Product Solution and Service

Table 36. Date of Enter into Targeted Drugs for NSCLC Market

Table 37. Mergers & Acquisitions, Expansion Plans

Table 38. Global Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 39. Global Targeted Drugs for NSCLC Market Size Share by Type (2015-2020)

Table 40. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2021-2026)

Table 41. Global Targeted Drugs for NSCLC Market Size Share by Application (2015-2020)

Table 42. Global Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 43. Global Targeted Drugs for NSCLC Market Size Share by Application (2021-2026)

Table 44. North America Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US\$)

Table 45. North America Key Players Targeted Drugs for NSCLC Market Share (2019-2020)

Table 46. North America Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 47. North America Targeted Drugs for NSCLC Market Share by Type (2015-2020)

Table 48. North America Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 49. North America Targeted Drugs for NSCLC Market Share by Application (2015-2020)

Table 50. Europe Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US\$)

Table 51. Europe Key Players Targeted Drugs for NSCLC Market Share (2019-2020)

Table 52. Europe Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 53. Europe Targeted Drugs for NSCLC Market Share by Type (2015-2020)

Table 54. Europe Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 55. Europe Targeted Drugs for NSCLC Market Share by Application (2015-2020)

Table 56. China Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US\$)

Table 57. China Key Players Targeted Drugs for NSCLC Market Share (2019-2020)

Table 58. China Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 59. China Targeted Drugs for NSCLC Market Share by Type (2015-2020)

Table 60. China Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 61. China Targeted Drugs for NSCLC Market Share by Application (2015-2020)

Table 62. Japan Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US\$)

Table 63. Japan Key Players Targeted Drugs for NSCLC Market Share (2019-2020)

Table 64. Japan Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 65. Japan Targeted Drugs for NSCLC Market Share by Type (2015-2020)

Table 66. Japan Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 67. Japan Targeted Drugs for NSCLC Market Share by Application (2015-2020)

Table 68. Southeast Asia Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US\$)

Table 69. Southeast Asia Key Players Targeted Drugs for NSCLC Market Share (2019-2020)

Table 70. Southeast Asia Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 71. Southeast Asia Targeted Drugs for NSCLC Market Share by Type (2015-2020)

Table 72. Southeast Asia Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 73. Southeast Asia Targeted Drugs for NSCLC Market Share by Application (2015-2020)

Table 74. India Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US\$)

Table 75. India Key Players Targeted Drugs for NSCLC Market Share (2019-2020)

Table 76. India Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 77. India Targeted Drugs for NSCLC Market Share by Type (2015-2020)

Table 78. India Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 79. India Targeted Drugs for NSCLC Market Share by Application (2015-2020)

Table 80. Central & South America Key Players Targeted Drugs for NSCLC Revenue (2019-2020) (Million US\$)

Table 81. Central & South America Key Players Targeted Drugs for NSCLC Market Share (2019-2020)

Table 82. Central & South America Targeted Drugs for NSCLC Market Size by Type (2015-2020) (Million US\$)

Table 83. Central & South America Targeted Drugs for NSCLC Market Share by Type (2015-2020)

Table 84. Central & South America Targeted Drugs for NSCLC Market Size by Application (2015-2020) (Million US\$)

Table 85. Central & South America Targeted Drugs for NSCLC Market Share by Application (2015-2020)

Table 86. Allergan Company Details

Table 87. Allergan Business Overview

Table 88. Allergan Product

Table 89. Allergan Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 90. Allergan Recent Development

Table 91. Amgen Company Details

Table 92. Amgen Business Overview

Table 93. Amgen Product

Table 94. Amgen Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 95. Amgen Recent Development

Table 96. ARIAD Pharmaceuticals (Takeda) Company Details

Table 97. ARIAD Pharmaceuticals (Takeda) Business Overview

Table 98. ARIAD Pharmaceuticals (Takeda) Product

Table 99. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 100. ARIAD Pharmaceuticals (Takeda) Recent Development

Table 101. Beacon Pharma Limited Company Details

Table 102. Beacon Pharma Limited Business Overview

Table 103. Beacon Pharma Limited Product

Table 104. Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 105. Beacon Pharma Limited Recent Development

Table 106. BeiGene Company Details

Table 107. BeiGene Business Overview

Table 108. BeiGene Product

Table 109. BeiGene Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 110. BeiGene Recent Development

Table 111. Biocon Company Details

Table 112. Biocon Business Overview

Table 113. Biocon Product

Table 114. Biocon Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 115. Biocon Recent Development

Table 116. Boehringer-Ingelheim Company Details

Table 117. Boehringer-Ingelheim Business Overview

Table 118. Boehringer-Ingelheim Product

Table 119. Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 120. Boehringer-Ingelheim Recent Development

Table 121. Celgene Corporation Business Overview

Table 122. Celgene Corporation Product

Table 123. Celgene Corporation Company Details

Table 124. Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 125. Celgene Corporation Recent Development

Table 126. Drug International Limited Company Details

Table 127. Drug International Limited Business Overview

Table 128. Drug International Limited Product

Table 129. Drug International Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 130. Drug International Limited Recent Development

Table 131. Fujifilm Kyowa Kirin Biologics Company Details

Table 132. Fujifilm Kyowa Kirin Biologics Business Overview

Table 133. Fujifilm Kyowa Kirin Biologics Product

Table 134. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 135. Fujifilm Kyowa Kirin Biologics Recent Development

- Table 136. Genvio Pharma Limited Company Details
- Table 137. Genvio Pharma Limited Business Overview
- Table 138. Genvio Pharma Limited Product
- Table 139. Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)
- Table 140. Genvio Pharma Limited Recent Development
- Table 141. Hetero Drugs Company Details
- Table 142. Hetero Drugs Business Overview
- Table 143. Hetero Drugs Product
- Table 144. Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)
- Table 145. Hetero Drugs Recent Development
- Table 146. ImClone Systems ?(Eli Lilly) Company Details
- Table 147. ImClone Systems ?(Eli Lilly) Business Overview
- Table 148. ImClone Systems ?(Eli Lilly) Product
- Table 149. ImClone Systems ?(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)
- Table 150. ImClone Systems ?(Eli Lilly) Recent Development
- Table 151. Incepta Pharmaceuticals Company Details
- Table 152. Incepta Pharmaceuticals Business Overview
- Table 153. Incepta Pharmaceuticals Product
- Table 154. Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)
- Table 155. Incepta Pharmaceuticals Recent Development
- Table 156. Mylan Company Details
- Table 157. Mylan Business Overview
- Table 158. Mylan Product
- Table 159. Mylan Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)
- Table 160. Mylan Recent Development
- Table 161. Novartis Company Details
- Table 162. Novartis Business Overview
- Table 163. Novartis Product
- Table 164. Novartis Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)
- Table 165. Novartis Recent Development
- Table 166. Pfizer Company Details
- Table 167. Pfizer Business Overview
- Table 168. Pfizer Product

Table 169. Pfizer Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 170. Pfizer Recent Development

Table 171. Reliance Lifesciences Company Details

Table 172. Reliance Lifesciences Business Overview

Table 173. Reliance Lifesciences Product

Table 174. Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 175. Reliance Lifesciences Recent Development

Table 176. Roche Company Details

Table 177. Roche Business Overview

Table 178. Roche Product

Table 179. Roche Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 180. Roche Recent Development

Table 181. AstraZeneca Company Details

Table 182. AstraZeneca Business Overview

Table 183. AstraZeneca Product

Table 184. AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 185. AstraZeneca Recent Development

Table 186. Cipla Company Details

Table 187. Cipla Business Overview

Table 188. Cipla Product

Table 189. Cipla Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 190. Cipla Recent Development

Table 191. Teva Company Details

Table 192. Teva Business Overview

Table 193. Teva Product

Table 194. Teva Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 195. Teva Recent Development

Table 196. OSI Pharmaceuticals Company Details

Table 197. OSI Pharmaceuticals Business Overview

Table 198. OSI Pharmaceuticals Product

Table 199. OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 200. OSI Pharmaceuticals Recent Development

Table 201. Glenmark Pharmaceuticals Company Details

Table 202. Glenmark Pharmaceuticals Business Overview

Table 203. Glenmark Pharmaceuticals Product

Table 204. Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 205. Glenmark Pharmaceuticals Recent Development

Table 206. Natco Pharma Company Details

Table 207. Natco Pharma Business Overview

Table 208. Natco Pharma Product

Table 209. Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2015-2020) (Million US\$)

Table 210. Natco Pharma Recent Development

Table 211. Research Programs/Design for This Report

Table 212. Key Data Information from Secondary Sources

Table 213. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Targeted Drugs for NSCLC Market Share by Type: 2020 VS 2026
- Figure 2. Target EGFR Features
- Figure 3. Target ALK Features
- Figure 4. Target HER2 Features
- Figure 5. Target ROS1 Features
- Figure 6. Target BRAF Features
- Figure 7. Target MEK Features
- Figure 8. Target VEGFR2 Features
- Figure 9. Target VEGF Features
- Figure 10. Target MET Features
- Figure 11. Global Targeted Drugs for NSCLC Market Share by Application: 2020 VS 2026
- Figure 12. Squamous Cell Carcinoma of NSCLC Case Studies
- Figure 13. Adenocarcinoma of NSCLC Case Studies
- Figure 14. Large Cell Carcinoma of NSCLC Case Studies
- Figure 15. Targeted Drugs for NSCLC Report Years Considered
- Figure 16. Global Targeted Drugs for NSCLC Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 17. Global Targeted Drugs for NSCLC Market Share by Regions: 2020 VS 2026
- Figure 18. Global Targeted Drugs for NSCLC Market Share by Regions (2021-2026)
- Figure 19. Porter's Five Forces Analysis
- Figure 20. Global Targeted Drugs for NSCLC Market Share by Players in 2019
- Figure 21. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for NSCLC as of 2019)
- Figure 22. The Top 10 and 5 Players Market Share by Targeted Drugs for NSCLC Revenue in 2019
- Figure 23. North America Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 24. Europe Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 25. China Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 26. Japan Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 27. Southeast Asia Targeted Drugs for NSCLC Market Size YoY Growth

(2015-2020) (Million US\$)

Figure 28. India Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 29. Central & South America Targeted Drugs for NSCLC Market Size YoY Growth (2015-2020) (Million US\$)

Figure 30. Allergan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. Allergan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 32. Amgen Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Amgen Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 34. ARIAD Pharmaceuticals (Takeda) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 36. Beacon Pharma Limited Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Beacon Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 38. BeiGene Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. BeiGene Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 40. Biocon Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Biocon Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 42. Boehringer-Ingelheim Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. Boehringer-Ingelheim Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 44. Celgene Corporation Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. Celgene Corporation Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 46. Drug International Limited Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. Drug International Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 48. Fujifilm Kyowa Kirin Biologics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 50. Genvio Pharma Limited Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. Genvio Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 52. Hetero Drugs Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 53. Hetero Drugs Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 54. ImClone Systems (Eli Lilly) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 55. ImClone Systems (Eli Lilly) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 56. Incepta Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 57. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 58. Mylan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 59. Mylan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 60. Novartis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 61. Novartis Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 62. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 63. Pfizer Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 64. Reliance Lifesciences Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 65. Reliance Lifesciences Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 66. Roche Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 67. Roche Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 68. AstraZeneca Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 69. AstraZeneca Revenue Growth Rate in Targeted Drugs for NSCLC Business (2015-2020)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Targeted Drugs for NSCLC Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C693BF5793B3EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C693BF5793B3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

